ONC:NASDAQ
BeOne Medicines AG
358,07 $
arrow_downward
-0,20%(-0,70) 1D
358,07 $
0,00% (0,00)
bedtimeAfter hours
Closed: 2 հոկ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ONC...
Open
351,01 $
High
358,57 $
Low
349,74 $
Mkt. cap
43,13 մլրդ
Avg. vol.
364,38 հզր
Volume
505,17 հզր
52-wk high
385,22 $
52-wk low
253,95 $
Beta
0,61
Shares outstanding
109,79 մլն
No. of employees
12 հզր
Open
351,01 $
High
358,57 $
Low
349,74 $
Mkt. cap
43,13 մլրդ
Avg. vol.
364,38 հզր
Volume
505,17 հզր
52-wk high
385,22 $
52-wk low
253,95 $
Beta
0,61
Shares outstanding
109,79 մլն
No. of employees
12 հզր
News stories
From web sources and news partners
Investor's Business Daily
·
3 օր առաջ
Biotech Leader BeOne Medicines Poised To Hit Early Buy Points
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12 հզր
Founded28 հոկ, 2010 թ.
Headquarters-
Sector-
Websitebeonemedicines.com